Tessellate Bio

Tessellate Bio is a biotechnology company founded in 2022, specializing in innovative synthetic lethality approaches to develop precision oncology medicines. The company aims to address unmet needs in cancer treatment, focusing on turning cancer patients into survivors. Tessellate Bio emerged from stealth in October 2023 and operates internationally, with its primary research and development facilities located at the Stevenage Bioscience Catalyst in the UK, and its headquarters in Amsterdam, Netherlands. The company is currently in the preclinical stage, working on first-in-class tumor-targeting medicines. Its key programs include the ALT Program, which targets cancers dependent on Alternative Lengthening of Telomeres, and the Loss-of-Function Program, focusing on tumors with specific vulnerabilities. Tessellate Bio is backed by significant seed funding from BioGeneration Ventures and Forbion, and it plans to expand its pipeline further. The leadership team brings extensive experience in drug discovery and oncology, positioning Tessellate Bio for growth in the biotechnology sector.